Summary of Key Points Core Viewpoint - On October 15, 37 Hong Kong-listed companies conducted share buybacks, totaling 34.04 million shares and an aggregate amount of HKD 167 million [1]. Group 1: Buyback Details - Xiaomi Group-W repurchased 2 million shares for HKD 98.96 million, with a highest price of HKD 49.54 and a lowest price of HKD 49.42, bringing its total buyback amount for the year to HKD 852 million [1][2]. - Four Seasons Pharmaceutical repurchased 10 million shares for HKD 15.19 million, with a highest price of HKD 1.54 and a lowest price of HKD 1.50, totaling HKD 12.16 million in buybacks for the year [1][2]. - Cloud Factory repurchased 2 million shares for HKD 8.01 million, with a highest price of HKD 4.05 and a lowest price of HKD 3.98, accumulating HKD 86.80 million in buybacks for the year [1][2]. Group 2: Buyback Rankings - The highest buyback amount on October 15 was from Xiaomi Group-W at HKD 98.96 million, followed by Four Seasons Pharmaceutical at HKD 15.19 million [1][2]. - In terms of share quantity, Four Seasons Pharmaceutical led with 10 million shares repurchased, followed by Anton Oilfield Services and China Electric Power Technology with 4.69 million and 4.60 million shares, respectively [1][2]. Group 3: Additional Buyback Information - Morning News Technology conducted its first buyback of the year on this date [2]. - A detailed table of buybacks includes various companies, their respective share counts, buyback amounts, highest and lowest prices, and cumulative buyback amounts for the year [2][3].

Group 1 - A total of 37 Hong Kong stocks conducted share buybacks on October 15, with 2 stocks exceeding HKD 10 million in buyback amounts [1] - The largest buyback amounts were recorded by Xiaomi Group-W (HKD 98.96 million), Sihuan Pharmaceutical (HKD 15.19 million), and Yun Gong Chang (HKD 8.01 million) [1] - Year-to-date, 240 Hong Kong stocks have conducted buybacks, with 53 stocks having cumulative buyback amounts exceeding HKD 100 million [1] Group 2 - The companies with the largest cumulative buyback amounts this year include Tencent Holdings (HKD 60.97 billion), HSBC Holdings (HKD 29.41 billion), and AIA Group (HKD 17.69 billion) [1]

Core Viewpoint - Four Seasons Pharmaceutical has been actively repurchasing its shares, indicating a strategy to enhance shareholder value amidst market fluctuations [2] Summary by Category Share Buyback Activity - On October 15, Four Seasons Pharmaceutical repurchased 10 million shares at prices ranging from 1.500 to 1.540 HKD, totaling 15.189 million HKD [2] - The stock closed at 1.530 HKD on the same day, reflecting a decline of 1.92%, with a total trading volume of 205 million HKD [2] - Year-to-date, the company has conducted 14 buybacks, acquiring a total of 141 million shares for an aggregate amount of 122 million HKD [2] Buyback Details - The buyback details are as follows: - October 15: 1,000,000 shares at a maximum price of 1.540 HKD and a minimum of 1.500 HKD, totaling 15.189 million HKD - September 26: 150,000 shares at 1.480 HKD, totaling 2.22 million HKD - September 2: 1,309,600 shares at 1.510 HKD, totaling 19.572 million HKD - June 17: 2,000,000 shares at 1.100 HKD, totaling 21.82 million HKD - May 12: 1,000,000 shares at 0.700 HKD, totaling 0.689 million HKD - May 6: 2,000,000 shares at 0.740 HKD, totaling 1.468 million HKD - May 2: 268,200 shares at 0.710 HKD, totaling 0.190 million HKD - April 30: 68,500 shares at 0.710 HKD, totaling 0.049 million HKD - April 29: 187,400 shares at 0.690 HKD, totaling 0.129 million HKD - April 28: 1,617,400 shares at 0.680 HKD, totaling 1.089 million HKD - April 16: 1,000,000 shares at 0.640 HKD, totaling 0.627 million HKD - April 9: 1,000,000 shares at 0.600 HKD, totaling 0.587 million HKD - April 7: 1,500,000 shares at 0.600 HKD, totaling 0.875 million HKD - February 11: 1,000,000 shares at 0.580 HKD, totaling 0.572 million HKD [2]

Core Viewpoint - The successful debut of Xuan Bamboo Biotech (02575.HK) on the Hong Kong Stock Exchange, with a first-day surge of 126.72%, reflects a positive market sentiment towards biotech stocks, particularly those listed under the 18A category [1][3][7] Company Overview - Xuan Bamboo Biotech is a subsidiary of Sihuan Pharmaceutical (00460.HK) and has previously attempted to list on the STAR Market without success [1][3] - The company has three approved products and is actively developing over ten drug assets targeting various diseases, including gastrointestinal disorders, tumors, and non-alcoholic fatty liver disease [3][4] Financial Performance - Despite the successful listing, Xuan Bamboo Biotech reported continuous losses, with projected losses increasing in 2024. Revenue figures for 2023 and 2024 are 29,000 yuan and 30.09 million yuan, respectively, with losses of 301 million yuan and 556 million yuan for the same periods [5][6] - The increase in losses is attributed to reduced revenue and rising administrative expenses, particularly due to stock-based compensation for management and staff [6] Market Sentiment and Trends - The recent performance of 18A new stocks, including Xuan Bamboo Biotech, indicates a recovery in investor confidence in the biotech sector, with several stocks experiencing significant first-day gains [1][7] - The overall market sentiment towards the biotech industry has improved, driven by increased global focus on biopharmaceutical research and technological advancements [7]

格隆汇10月15日丨四环医药(00460.HK)公告，10月15日耗资1519万港元回购1000万股。 ...

四环医药(00460)发布公告，该公司于2025年10月15日斥资1518.9万港元回购1000万股股份，每股回购价 格为1.5-1.54港元。 ...

智通财经APP讯，四环医药(00460)发布公告，该公司于2025年10月15日斥资1518.9万港元回购1000万股 股份，每股回购价格为1.5-1.54港元。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 Sihuan Pharmaceutical Holdings Group Ltd. 四環醫藥控股集團有限公司 關於四環醫藥 四 環 醫 藥 創 立 於 二 零 零 一 年，二 零 一 零 年 於 聯 交 所 主 板 上 市，是 一 家 以 創 新 為 引 領，擁 有 獨 立 領 先 的 自 主 研 發 技 術 平 台、具 備 豐 富 的 全 球 化 產 品 管 線、強 大 的 產 品 註 冊 能 力、高 效 率 及 低 成 本 的 全 劑 型 生 產 平 台 和 成 熟 卓 越 銷 售 體 系 的 國 際 化 制 藥 及 醫 美 企 業。四 環 醫 藥 一 直 秉 承「堅 持 全 速 推 進 四 環 醫 美 及 生 物 制 藥 雙 輪 驅 動 戰 略」的 整 體 戰 略 目 標 來 打 造 中 國 領 先 醫 美 及 生 物 制 藥 企 業。 本 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 四環醫藥控股集團有限公司 呈交日期： 2025年10月15日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 第 1 頁 共 6 頁 v 1.3.0 FF305 確認 不適用 第一章節註釋： 若股份曾以超過一個每股價格發行/出售/購回/贖回，則須提供每股成交量加權平均價格。 若購回/贖回股份將於期終結存日期之後購回/贖回結算完成之時予以註銷，則該等購回/贖回股份仍屬A部所述期終結存當日的已發行股份的一部分。該等購回/贖回股份的詳情應在B部作 出披露。 第 2 頁 共 6 頁 v 1.3.0 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 ...

格隆汇10月15日丨四环医药(00460.HK)发布公告，2025年10月15日，受托人已就股份奖励计划于市场上 购买合共925.5万股公司股份。 ...